Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Zerebral metastasiertes Dermatofibrosarcoma protuberans.
J Dtsch Dermatol Ges. 2020 Feb;18(2):143-146. doi: 10.1111/ddg.13992_g.
J Dtsch Dermatol Ges. 2020.
PMID: 32026638
German.
No abstract available.
Cerebral metastases of a dermatofibrosarcoma protuberans.
Zielonka M, Debatin D, Rütten A, Fröhling S, Deimling A, Warth A, Toberer F, Enk AH, Hassel JC.
Zielonka M, et al. Among authors: debatin d.
J Dtsch Dermatol Ges. 2020 Feb;18(2):143-145. doi: 10.1111/ddg.13992. Epub 2019 Dec 17.
J Dtsch Dermatol Ges. 2020.
PMID: 31846212
No abstract available.
Item in Clipboard
Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers.
Zschäbitz S, Vallet S, Hadaschik B, Debatin D, Fuxius S, Karcher A, Pahernik S, Spath C, Duensing S, Jäger D, Hohenfellner M, Grüllich C.
Zschäbitz S, et al. Among authors: debatin d.
J Cancer. 2017 Feb 11;8(4):507-512. doi: 10.7150/jca.17644. eCollection 2017.
J Cancer. 2017.
PMID: 28367230
Free PMC article.
Item in Clipboard
De novo CSF3R mutation associated with transformation of myeloproliferative neoplasm to atypical CML.
Bartels S, Lehmann U, Büsche G, Schlue J, Hussein K, Debatin D, Karcher A, Andrulis M, Schirmacher P, Kreipe H.
Bartels S, et al. Among authors: debatin d.
Ann Hematol. 2015 Jul;94(7):1255-6. doi: 10.1007/s00277-015-2366-3. Epub 2015 Apr 14.
Ann Hematol. 2015.
PMID: 25865944
No abstract available.
Item in Clipboard
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators.
Goldschmidt H, et al.
Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0.
Lancet Haematol. 2022.
PMID: 36328040
Clinical Trial.
Item in Clipboard
Cite
Cite